Erlotinib

Generic Name
Erlotinib
Brand Names
Tarceva
Drug Type
Small Molecule
Chemical Formula
C22H23N3O4
CAS Number
183321-74-6
Unique Ingredient Identifier
J4T82NDH7E
Background

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication

Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions
Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
Associated Therapies
-
Clinical Trials
Related News

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: MM-121
Drug: Erlotinib
First Posted Date
2009-10-14
Last Posted Date
2016-08-22
Lead Sponsor
Merrimack Pharmaceuticals
Target Recruit Count
162
Registration Number
NCT00994123

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

First Posted Date
2009-09-24
Last Posted Date
2018-01-30
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
17
Registration Number
NCT00983307
Locations
🇺🇸

Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States

🇺🇸

Thomas Jefferson Univeristy, Philadelphia, Pennsylvania, United States

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Phase 2
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: Erlotinib
First Posted Date
2009-09-15
Last Posted Date
2013-09-16
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
39
Registration Number
NCT00977548
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

First Posted Date
2009-09-15
Last Posted Date
2020-07-14
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
76
Registration Number
NCT00977470
Locations
🇺🇸

Stanford Cancer Institute, Stanford, California, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

University of Maryland, Baltimore, Maryland, United States

and more 1 locations

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Phase 1
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Erlotinib
Drug: PF-02341066
First Posted Date
2009-08-26
Last Posted Date
2015-10-28
Lead Sponsor
Pfizer
Target Recruit Count
27
Registration Number
NCT00965731
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Holy Cross Hospital, Fort Lauderdale, Florida, United States

🇺🇸

James Care in Kenny, Columbus, Ohio, United States

and more 12 locations

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

First Posted Date
2009-08-07
Last Posted Date
2018-08-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
15
Registration Number
NCT00954512

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 4
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Erlotinib
First Posted Date
2009-07-31
Last Posted Date
2016-10-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
6586
Registration Number
NCT00949910

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

First Posted Date
2009-07-27
Last Posted Date
2017-03-03
Lead Sponsor
Pamela L. Kunz
Target Recruit Count
4
Registration Number
NCT00947167
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2
Completed
Conditions
Head And Neck Cancer
Interventions
Drug: Erlotinib
Drug: RAD001
First Posted Date
2009-07-21
Last Posted Date
2023-10-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
49
Registration Number
NCT00942734
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

First Posted Date
2009-05-25
Last Posted Date
2009-05-25
Lead Sponsor
Hospital Arnau de Vilanova
Target Recruit Count
70
Registration Number
NCT00908336
Locations
🇪🇸

Hospital General de Elda, Elda, Alicante, Spain

🇪🇸

Hospital Provincial de Castellón, Castellón de la Plana, Castellón, Spain

🇪🇸

Hospital Virgen de los Lirios, Alcoy, Alicante, Spain

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy